MedStar Georgetown University Hospital (MGUH)
Welcome,         Profile    Billing    Logout  
 9 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Noel, Marcus
NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting
3
480
US
Glufosfamide, Fluorouracil, 5-FU
Eleison Pharmaceuticals LLC.
Metastatic Pancreatic Adenocarcinoma
06/25
12/25
SGNTUC-019, NCT04579380: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Recruiting
1/2
258
US, RoW
TAK-186, MVC-101
Takeda
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
09/25
11/26
NCT04292743: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
19
US
Eryaspase, FOLFIRINOX, 5-fluorouracil, oxaliplatin, Irinotecan, leucovorin
Georgetown University, ERYtech Pharma
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
01/23
07/24
Weinberg, Benjamin
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NAPOLI-2, NCT04005339: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Recruiting
2
44
US
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Georgetown University, Ipsen
Advanced Biliary Tract Cancer
05/24
07/24
DARANIVOVAX, NCT06015724: Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Recruiting
2
54
US
Daratumumab, Darzalex Faspro, KRAS vaccine, Nivolumab, BMS-936558
Georgetown University, Bristol-Myers Squibb, Janssen, LP, Targovax ASA
Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
01/25
01/26
EXPEL PANC, NCT05558982: BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
2
43
US
BXCL701, Pembrolizumab, Keytruda
Georgetown University, BioXcel Therapeutics Inc, Merck Sharp & Dohme LLC
Metastatic Pancreatic Ductal Adenocarcinoma
11/26
11/27
NCT02985125: LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Active, not recruiting
1/2
44
US
LEE011, ribociclib, Everolimus, Afinitor®
Georgetown University, Novartis, University of Texas Southwestern Medical Center, Cedars-Sinai Medical Center, Virginia Mason Hospital/Medical Center
Metastatic Pancreatic Adenocarcinoma
12/20
12/22
NCT05661201: NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Recruiting
1
24
US
NEROFE, Doxorubicin, adriamycin
Georgetown University, Immune System Key Ltd
Solid Tumor, KRAS Mutation-Related Tumors
01/26
01/26
NCT04566393: Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Available
N/A
US
Ulixertinib (BVD-523)
xCures, Cancer Commons
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
 
 
Macke, Laura
No trials found

Download Options